Immunome, Inc. (IMNM)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Feb 14, 2025

$10.40

P/E Ratio

N/A

Market Cap

$880.62M

Description
Add to research

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Metrics
Add to research

Overview

  • HQBothell, WA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerIMNM
  • Price$10.4-0.29%

Trading Information

  • Market cap$880.62M
  • Float82.26%
  • Average Daily Volume (1m)1,195,350
  • Average Daily Volume (3m)971,468
  • EPS-$8.12

Company

  • Revenue$10.13M
  • Rev growth (1yr)-18.37%
  • Net income-$47.10M
  • Gross margin80.38%
  • EBITDA margin-1,486.08%
  • EBITDA-$43.25M
  • EV$642.79M
  • EV/Revenue63.46
  • P/EN/A
  • P/S61.82
  • P/B2.92
  • Debt/Equity1.27
Documents
Add to research